

with impairment of cardiac function, hypokalaemia, or other electrolyte imbalance. It is recommended that a baseline ECG is performed in all patients before use of droperidol.

Uses and Administration

Droperidol is a butyrophenone with general properties similar to those of haloperidol (p.1001). The duration of action of droperidol has been reported to last about 2 to 4 hours although alteration of alertness may last for up to 12 hours.

One manufacturer of droperidol (*Janssen-Cilag*) voluntarily withdrew it from the market worldwide in March 2001 after reports of QT prolongation, serious ventricular arrhythmias, or sudden death in association with its use. However, in the USA, droperidol remained available from other manufacturers although its use was restricted to the management of nausea and vomiting after surgical or diagnostic procedures in patients who fail to show an adequate response to other treatments. It is also still available, in some other countries, for use as a premedicant, as an adjunct in anaesthesia, and for the control of agitated patients in acute psychoses and in mania. Droperidol has been used in the management of chemotherapy-induced nausea and vomiting. It has also been used with an opioid analgesic such as fentanyl citrate to maintain patients in a state of neuroleptanalgesia in which they are calm and indifferent to the surroundings and able to cooperate with the surgeon. The longer duration of action of droperidol must be kept in mind when using it with such opioid analgesics.

For the prevention of postoperative nausea and vomiting a maximum initial dose of 2.5 mg intramuscularly or intravenously has been given; additional doses of 1.25 mg may be given if necessary. Children aged 2 years and over have been given a maximum initial dose of 100 micrograms/kg intramuscularly or intravenously.

References.

- McKeage K, *et al.* Intravenous droperidol: a review of its use in the management of postoperative nausea and vomiting. *Drugs* 2006; **66**: 2123-47.

Preparations

BP 2008: Droperidol Injection; Droperidol Tablets;
USP 31: Droperidol Injection.

Proprietary Preparations (details are given in Part 3)

Austral.: Droleptan; **Belg.:** Dehydrobenzperidol; **Braz.:** Droperdal; **Cz.:** Dehydrobenzperidol; **Xomolox.:** Dehydrobenzperidol; **Fin.:** Dehydrobenzperidol; **Fr.:** Droleptan; **Gr.:** Dehydrobenzperidol; **Droleptan;** **India:** Droperol; **Ital.:** Sintodian†; **Neth.:** Dehydrobenzperidol; **NZ:** Droleptan; **Port.:** Dehydrobenzperidol; **Xomolox. S.Afr.:** Paxical; **Spain:** Dehydrobenzperidol†; **Swed.:** Dridol; **Thai.:** Dehydrobenzperidol†; **USA:** Inapsine.

Multi-ingredient: **Arg.:** Disifelit; **Braz.:** Nilperidol; **Ital.:** Leptofen.

Estazolam (USAN, rINN)

Abbott-47631; D-40TA; Estatsolaam; Estazolamum. 8-Chloro-6-phenyl-4H-1,2,4-triazolo[4,3-*a*]-1,4-benzodiazepine.


Эстазолам

$C_{16}H_{11}ClN_4 = 294.7$.

CAS — 29975-16-4.

ATC — N05CD04.

ATC Vet — QN05CD04.



Pharmacopoeias. In *Chin.* and *Jpn.*

Dependence and Withdrawal

As for Diazepam, p.987.

Adverse Effects, Treatment, and Precautions

As for Diazepam, p.987.

Interactions

As for Diazepam, p.989.

Pharmacokinetics

Peak plasma concentrations of estazolam are reached on average within 2 hours of oral doses. Estazolam is about 93% protein bound. Reported mean elimination half-lives have generally been in the range of 10 to 24 hours. Estazolam is extensively metabolised, mainly to 4-hydroxyestazolam and 1-oxoestazolam, which are considered inactive. These metabolites are excreted, either free or conjugated, in the urine with small amounts detected in the faeces. Only a small proportion of a dose is excreted as unchanged drug.

The symbol † denotes a preparation no longer actively marketed

Uses and Administration

Estazolam is a short-acting benzodiazepine with general properties similar to those of diazepam (p.992). It is given as a hypnotic in the short-term management of insomnia (p.957) in usual oral doses of 1 to 2 mg at night. Small or debilitated elderly patients may be given an initial dose of 0.5 mg.

Preparations

Proprietary Preparations (details are given in Part 3)

Arg.: Somnatrol†; **Braz.:** Noctal; **Denm.:** Domnamid†; **Fr.:** Nuctalon; **In-don.:** Esilgan; **Ital.:** Esilgan; **Jpn.:** Eurodin; **Mex.:** Tasedan; **Philipp.:** Esilgan; **Port.:** Kainever; **USA:** Prosom†.


Eszopiclone (USAN, rINN)

Eszopiclone; Eszopiclonum; (S)-Zopiclone; (+)-Zopiclone. (+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate.

Эсзопикльон

$C_{17}H_{17}ClN_6O_3 = 388.8$.

CAS — 138729-47-2.



NOTE. The following terms have been used as 'street names' (see p.vi) or slang names for various forms of eszopiclone: Sleepeasy.

Profile

Eszopiclone is the (+)-isomer of zopiclone (p.1039) and is used similarly as a hypnotic in the short-term management of insomnia.

The usual oral dose is 2 mg immediately before bedtime; if appropriate, the dose may be started at or increased to 3 mg. In elderly patients who have difficulty falling asleep, the initial dose is 1 mg; this may be increased to 2 mg. For elderly patients who have difficulty staying asleep, the starting dose is 2 mg.

The starting dose should be reduced in patients taking potent inhibitors of the cytochrome P450 isoenzyme CYP3A4; a dose not exceeding 1 mg is recommended which may then be increased to 2 mg. For doses in patients with hepatic impairment, see below.

Reviews.

- Melton ST, *et al.* Eszopiclone for insomnia. *Ann Pharmacother* 2005; **39**: 1659-66.
- Halas CJ. Eszopiclone. *Am J Health-Syst Pharm* 2006; **63**: 41-8.

Administration in hepatic impairment. The starting oral dose of eszopiclone should be reduced to 1 mg at bedtime in patients with severe hepatic impairment. No dose adjustment is necessary in patients with mild to moderate impairment.

Preparations

Proprietary Preparations (details are given in Part 3)

Arg.: Inductal; **USA:** Lunesta.

Ethchlorvynol (BAN, rINN)

β -Chlorovinyl Ethyl Ethynyl Carbinol; Etclorvinol; Éthchlorvynol; E-Ethchlorvynol; Ethchlorvynolum; Etkloorvinoli; Etklorvinol. 1-Chloro-3-ethylpent-1-en-4-yn-3-ol.


Этхлорвинол

$C_7H_9ClO = 144.6$.

CAS — 113-18-8.

ATC — N05CM08.

ATC Vet — QN05CM08.



Pharmacopoeias. In *US*.

USP 31 (Ethchlorvynol). A colourless to yellow, slightly viscous liquid having a characteristic pungent odour. It darkens on exposure to air and light. Immiscible with water; miscible with most organic solvents. Store in airtight containers of glass or polyethylene, using polyethylene-lined closures. Protect from light.

Dependence and Withdrawal

Prolonged use of ethchlorvynol may lead to dependence similar to that with barbiturates (see Amobarbital, p.962).

Adverse Effects

Adverse effects of ethchlorvynol include gastrointestinal disturbances, dizziness, headache, unwanted sedation and other symp-

oms of CNS depression such as ataxia, facial numbness, blurred vision, and hypotension. Hypersensitivity reactions include skin rashes, urticaria, and occasionally, thrombocytopenia and cholestatic jaundice. Idiosyncratic reactions include excitement, severe muscular weakness, and syncope without marked hypotension.

Acute overdosage is characterised by prolonged deep coma, respiratory depression, hypothermia, hypotension, and relative bradycardia. Pancytopenia and nystagmus have occurred.

Pulmonary oedema has followed abuse by intravenous injection.

Treatment of Adverse Effects

Treatment is as for barbiturate overdose (see Amobarbital, p.962). Haemoperfusion may be of value in the treatment of severe poisoning with ethchlorvynol.

Precautions

Ethchlorvynol should be used with caution in patients with hepatic or renal impairment or with depression, in patients with severe unrelieved pain, and, as with all sedatives, in those with impaired respiratory function. It may cause drowsiness; affected patients should not drive or operate machinery.

Excessively rapid absorption of ethchlorvynol in some patients has been reported to produce giddiness and ataxia; this may be reduced by giving it with food.

Porphyria. Ethchlorvynol has been associated with acute attacks of porphyria and is considered unsafe in porphyric patients.

Interactions

The effect of ethchlorvynol may be enhanced by alcohol, barbiturates, and other CNS depressants. Ethchlorvynol has been reported to decrease the effects of coumarin anticoagulants.

Tricyclic antidepressants. Transient delirium has been reported from the use of ethchlorvynol with *amitriptyline* but details of such an interaction do not appear to have been published in the literature.

Pharmacokinetics

Ethchlorvynol is readily absorbed from the gastrointestinal tract, peak plasma concentrations usually occurring within 2 hours of ingestion. It is widely distributed in body tissues and is extensively metabolised in the liver, and possibly to some extent in the kidneys. It has a biphasic plasma half-life with a rapid initial phase and a terminal phase reported to last from 10 to 20 hours. Ethchlorvynol is excreted mainly in the urine as metabolites and their conjugates. Ethchlorvynol crosses the placenta.

Uses and Administration

Ethchlorvynol is a hypnotic and sedative with some anticonvulsant and muscle relaxant properties. It is given for the short-term management of insomnia (p.957) but has been largely superseded by other drugs. Use for periods greater than one week is not recommended. The usual oral hypnotic dose is 500 mg at night but doses ranging from 200 mg to 1 g have been given. Taking doses with food has been recommended—see Precautions, above.

Preparations

USP 31: Ethchlorvynol Capsules.

Ethyl Loflazepate (rINN)

CM-6912; Ethyle, Loflazépaté d'; Ethylis Loflazepas; Loflazepato de etilo. Ethyl 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepine-3-carboxylate.


Этил Лофлазепат

$C_{18}H_{14}ClFN_2O_3 = 360.8$.

CAS — 29177-84-2.

ATC — N05BA18.

ATC Vet — QN05BA18.



Profile

Ethyl loflazepate is a long-acting benzodiazepine derivative with general properties similar to those of diazepam (p.986). It is used in the short-term treatment of anxiety disorders (p.952) in usual oral doses of 1 to 3 mg daily in a single dose or in divided doses.

Preparations

Proprietary Preparations (details are given in Part 3)

Arg.: Victan†; **Belg.:** Victan; **Fr.:** Victan; **Jpn.:** Meilax; **Mex.:** Victan; **Port.:** Victan; **Thai.:** Victan.